OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device ...

The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...

Biomedicines and its artificial intelligence platform to generate drugs for multiple undisclosed targets. Generate will receive $65 million up front, which includes an equity investment of $15 million ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.

Ben-Aharon declared financial interests with AstraZeneca, MSD and Merck (invited speaker), and Bristol Myers Squibb and ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

And when I look at KEYTRUDA back in 2019, internationally, we only had 12 indications. So over that time, the clinical development work and the regulatory teams at MSD have done a fantastic job. We're ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...